LakeShore Biopharma Co., Ltd (LSB) - Total Assets
Based on the latest financial reports, LakeShore Biopharma Co., Ltd (LSB) holds total assets worth $1.37 Billion USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
LakeShore Biopharma Co., Ltd - Total Assets Trend (2021–2025)
This chart illustrates how LakeShore Biopharma Co., Ltd's total assets have evolved over time, based on quarterly financial data. Also see LakeShore Biopharma Co., Ltd (LSB) total market value for the company's overall valuation and market capitalisation.
LakeShore Biopharma Co., Ltd - Asset Composition Analysis
Current Asset Composition (March 2025)
LakeShore Biopharma Co., Ltd's total assets of $1.37 Billion consist of 61.6% current assets and 38.4% non-current assets. Review LakeShore Biopharma Co., Ltd (LSB) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.1% |
| Accounts Receivable | $501.79 Million | 36.7% |
| Inventory | $227.59 Million | 16.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $72.85 Million | 5.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how LakeShore Biopharma Co., Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See LakeShore Biopharma Co., Ltd share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LakeShore Biopharma Co., Ltd's current assets represent 61.6% of total assets in 2025, a decrease from 802421.1% in 2021.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2025, down from 427317.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 91687.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 36.7% of total assets.
LakeShore Biopharma Co., Ltd Competitors by Total Assets
Key competitors of LakeShore Biopharma Co., Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
LakeShore Biopharma Co., Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.02 | 1.13 | 2.77 |
| Quick Ratio | 0.75 | 0.87 | 2.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $17.47 Million | $100.94 Million | $8.98 Million |
LakeShore Biopharma Co., Ltd - Advanced Valuation Insights
This section examines the relationship between LakeShore Biopharma Co., Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.49 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -9.6% |
| Total Assets | $1.37 Billion |
| Market Capitalization | $25.84 Million USD |
Valuation Analysis
Below Book Valuation: The market values LakeShore Biopharma Co., Ltd's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: LakeShore Biopharma Co., Ltd's assets decreased by 9.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for LakeShore Biopharma Co., Ltd (2021–2025)
The table below shows the annual total assets of LakeShore Biopharma Co., Ltd from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $1.37 Billion | -9.61% |
| 2024-03-31 | $1.51 Billion | -12.02% |
| 2023-03-31 | $1.72 Billion | +755.45% |
| 2022-03-31 | $201.03 Million | +219912.42% |
| 2021-03-31 | $91.37K | -- |
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS… Read more